RAMM Pharma Corp.

RAMM Pharma Corp. is involved in the complete cycle of researching, developing, manufacturing, and commercializing a diverse array of cannabinoid-derived products. The company's extensive portfolio, available both in Canada and across international markets, encompasses specialized cannabinoid pharmaceutical formulations, conventional pharmaceuticals, cosmetics, and nutritional supplements. Furthermore, RAMM Pharma Corp. functions as a reseller of medical supplies. Among its notable products are Epifractán, a pharmaceutical drug utilizing cannabinoids; XALEX 10, a prescription formulation specifically designed for treating refractory epilepsy; and NettaLife, a cannabis-based offering developed for animal use. Founded in 1987, the corporation operated under the name MTC Growth Fund-I Inc. until it formally adopted its current name, RAMM Pharma Corp., in October 2019. Its main offices are located in Toronto, Canada.